Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

November 26, 2024

Study Completion Date

November 26, 2024

Conditions
High Grade Glioma
Interventions
DRUG

Nivolumab

"Solution for intravenous injection 10 mg/ml. Initial dose : 3 mg/kg Nivolumab will be given at 3 mg/kg/injection every two weeks from the first day of radiotherapy to the last day of chemotherapy.~One de-escalation dose : 1 mg/kg"

DRUG

Temozolomide

Capsules: 5, 20, 100, 140, 180 and 250 mg orally. Temozolomide will be given at 75mg/m2/day from the day of start of radiotherapy to the last day of radiotherapy, then, after one month rest at 200mg/m2/day for five consecutive days for 12 cycles (28 days cycle).

RADIATION

Radiotherapy

Total dose of 54 Gray(Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation period.

Trial Locations (7)

31300

Hôpital des enfants, Toulouse

49100

CHU Angers, Angers

59000

Centre Oscar Lambret, Lille

67200

CHU Hautepierre, Strasbourg

69008

Centre Léon Bérard, Lyon

75005

Institut Curie, Paris

94800

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT04267146 - Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma | Biotech Hunter | Biotech Hunter